CN101180052A - Film coated preparation containing dextrose - Google Patents
Film coated preparation containing dextrose Download PDFInfo
- Publication number
- CN101180052A CN101180052A CNA2006800175368A CN200680017536A CN101180052A CN 101180052 A CN101180052 A CN 101180052A CN A2006800175368 A CNA2006800175368 A CN A2006800175368A CN 200680017536 A CN200680017536 A CN 200680017536A CN 101180052 A CN101180052 A CN 101180052A
- Authority
- CN
- China
- Prior art keywords
- film
- coated preparation
- thin layer
- coated
- preparation
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
- A61K9/2806—Coating materials
- A61K9/2833—Organic macromolecular compounds
- A61K9/286—Polysaccharides, e.g. gums; Cyclodextrin
- A61K9/2866—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/4164—1,3-Diazoles
- A61K31/4178—1,3-Diazoles not condensed 1,3-diazoles and containing further heterocyclic rings, e.g. pilocarpine, nitrofurantoin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/12—Drugs for disorders of the urinary system of the kidneys
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/04—Anorexiants; Antiobesity agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/12—Antihypertensives
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- Veterinary Medicine (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Epidemiology (AREA)
- Diabetes (AREA)
- Heart & Thoracic Surgery (AREA)
- Cardiology (AREA)
- Obesity (AREA)
- Urology & Nephrology (AREA)
- Hematology (AREA)
- Child & Adolescent Psychology (AREA)
- Vascular Medicine (AREA)
- Emergency Medicine (AREA)
- Endocrinology (AREA)
- Biochemistry (AREA)
- Molecular Biology (AREA)
- Oil, Petroleum & Natural Gas (AREA)
- Medicinal Preparation (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Abstract
The invention provides a film coated preparation which contains a smelling drug in its formulation and further contains dextrose in the film layer thereof.
Description
Technical field
The present invention relates to film-coated preparation.
Background technology
As everyone knows, in pharmaceuticals, have some to have the medicament that makes the abnormal flavour that the user feels unpleasant, and the preparation that contains this medicament not only make the user be difficult to accept, and also influences its commodity value.
In the prior art, for example can be made into coated tablet and come covering smell, become shortcoming big, that be difficult for taking but coated tablet has tablet.In addition, known use has mixed the thin membrane coated tablet of the thin layer coating of hydroxypropyl emthylcellulose, can cover the abnormal flavour beastly (TOHKEMY 2003-300883 communique) of medicament, but its effect that suppresses abnormal flavour is also insufficient.
Patent documentation 1: TOHKEMY 2003-300883 communique
Summary of the invention
The objective of the invention is, the film-coated preparation that can reduce the medicament abnormal flavour is provided.
To achieve these goals, the inventor makes great efforts after the research, is surprised to find by carrying out the abnormal flavour that coating can reduce prescription with the thin layer that has mixed dextrose, and then has finished the present invention.
Promptly, the present invention can provide,
(1) in prescription, contains medicament, contain the film-coated preparation of dextrose in the thin layer with abnormal flavour;
(2) in prescription, contain olmesartan medoxomil, contain the film-coated preparation of dextrose in the thin layer;
(3) in prescription, contain olmesartan medoxomil and other medicament simultaneously, contain the film-coated preparation of dextrose in the thin layer;
(4) in prescription, contain 2-amino-5-isobutyl group-4-{2-[5-(N, N '-two (S)-1-carbethoxyl group) phosphonic amide ethyl)] furan } thiazole (2-amino-5-isobutyl-4-{2-[5-(N, N '-bis ((S)-1-ethoxycarbonyl) ethyl) phosphonamido]-furanyl}thiazole), contain the film-coated preparation of dextrose in the thin layer;
(5), in thin layer, also contain the coated composition of coated substrate or excipient as any described film-coated preparation in above-mentioned (1)～(4);
(6) as above-mentioned (5) described film-coated preparation, this coated substrate or excipient are the chemical compounds more than a kind or 2 kinds that is selected from sodium carboxymethyl cellulose, hydroxymethyl propyl methylcellulose, hydroxypropyl cellulose, polyvinylpyrrolidone, polyvinyl alcohol, methylcellulose, ethyl cellulose, dextrin, maltodextrin, lactose, D-mannitol, polyvinyl alcohol polymer, methacrylic acid copolymer, methacrylic acid ammonia alkyl ester copolymer and the ethyl acrylate methylmethacrylate copolymer;
(7) as above-mentioned (5) described film-coated preparation, this coated substrate or excipient are sodium carboxymethyl cellulose;
(8) as any described film-coated preparation in above-mentioned (1)～(7), said preparation is a tablet;
(9) as any described film-coated preparation in above-mentioned (1)～(8) etc., thin layer is more than 1% (w/w) with respect to prescription weight;
(10) as any described film-coated preparation in above-mentioned (1)～(8), thin layer is more than 3% (w/w) with respect to prescription weight;
(11) as any described film-coated preparation in above-mentioned (1)～(8), thin layer is more than 6% (w/w) with respect to prescription weight;
(12) as any described film-coated preparation in above-mentioned (1)～(8), the film thickness of thin layer is more than 1 μ m;
(13) as any described film-coated preparation in above-mentioned (1)～(8), the film thickness of thin layer is more than 5 μ m;
(14) as any described film-coated preparation in above-mentioned (1)～(8), the film thickness of thin layer is more than 10 μ m;
(15) as any described film-coated preparation in above-mentioned (1)～(8), the film thickness of thin layer is more than 20 μ m.
According to the present invention, can provide the film-coated preparation that does not in fact have abnormal flavour, has the best possible merchandise performance.
The specific embodiment
Film-coated preparation involved in the present invention contains dextrose in thin layer.Therefore, the abnormal flavour that can effectively reduce medicament and had, and can obtain to change in time also stable film-coated preparation.The content of dextrose in thin layer does not just have particular restriction to it so long as can effectively reduce the amount of medicament abnormal flavour, but is limited to usually more than 20% (w/w), more than preferred 30% (w/w), more preferably more than 40% (w/w); On be limited to that 90% (w/w) is following, preferred 80% (w/w) following, more preferably below 70% (w/w).
In thin layer, can also mix coated substrate or excipient.Kind to coated substrate or excipient is not particularly limited, and the person of ordinary skill in the field can suitably select to use.This type of coated substrate or excipient for example comprise sodium carboxymethyl cellulose (CMCNa), polyvinylpyrrolidone (PVP), polyvinyl alcohol (PVA), methylcellulose, ethyl cellulose, hydroxypropyl cellulose (HPC), hydroxypropyl emthylcellulose (HPMC), dextrin, maltodextrin, lactose, D-mannitol, polyvinyl alcohol polymer, methacrylic acid copolymer, methacrylic acid ammonia alkyl ester copolymer and ethyl acrylate methylmethacrylate copolymer etc.Be preferably sodium carboxymethyl cellulose.
Again as required, in coated composition, can contain the additive more than 1 or 1 in plasticizer, excipient, lubricant, screening agent, coloring agent and the antiseptic etc. of general use amount.
Kind to the plasticizer that can use does not in the present invention have particular restriction, and described those skilled in the art can suitably select to use.This type of plasticizer for example comprises polyethylene glycol 6000, propylene glycol, Polyethylene Glycol, polypropylene glycol, glycerol and Sorbitol, glyceryl triacetate, diethyl phthalate and triethyl citrate, lauric acid, sucrose, dextrose, Sorbitol, glyceryl triacetate, acetyl triethyl citrate, triethyl citrate, tributyl citrate, tributyl 2-acetylcitrate etc.
The spendable excipient of the present invention for example comprises lactose, mannitol, crystal fibre element, maltodextrin etc.
The spendable lubricant of the present invention for example comprises Pulvis Talci, magnesium stearate, calcium stearate, stearic acid etc.
The spendable screening agent of the present invention for example comprises titanium oxide etc.
The spendable coloring agent of the present invention for example comprises titanium oxide, ferrum oxide, iron sesquioxide, yellow iron sesquioxide, yellow No. 5 aluminum color lake Pulvis Talci (aluminium lake talc) etc.
The spendable antiseptic of the present invention for example comprises p-Hydroxybenzoate (paraben) etc.
In the present invention, as the effective ingredient that is comprised by film-coated preparation, so long as have the medicine of abnormal flavour, just without limits to its structure, degree etc.Be preferably olmesartan medoxomil or 2-amino-5-isobutyl group-4-{2-[5-(N, N '-two ((S)-1-carbethoxyl group) ethyl) phosphonic amide] furan } thiazole, more preferably olmesartan medoxomil.And olmesartan medoxomil (is specially hypertension to hypertension or the disease that causes because of hypertension; Heart disease [angina pectoris, myocardial infarction, arrhythmia, heart failure or megalocardia]; Kidney disease [diabetic nephropathy, glomerulonephritis or Nephrosclerosis] or cerebrovascular [cerebral infarction or cerebral hemorrhage]) prevention and treatment effectively, can easily specially permit communique (United States Patent (USP) the 5th No. 2082519 according to Japan, 616, No. 599 communiques) etc. the method for being put down in writing and making.In addition, 2-amino-5-isobutyl group-4-{2-[5-(N, N '-two ((S)-1-carbethoxyl group) ethyl) phosphonic amide] furan } thiazole, to the prevention of diabetes, hyperglycemia, impaired glucose tolerance, obesity, diabetic complications etc. or treatment effectively (prevention or the treatments of preferred diabetes), can be easily according to the world method manufacturing that the 01/47935th trumpeter's volume etc. is put down in writing be disclosed.
And film-coated preparation of the present invention can also contain other effective ingredient as required.This effective ingredient for example comprises trichlormethiazide (Trichloromethiazide), hydrochlorothiazide (Hydrochlorothiazide), behyd diuretic such as (Benzylhydrochlorothiazide); Azelnidipine (Azelnidipine), amlodipine (Amlodipine), benidipine (Benidipine), nitrendipine (Nitrendipine), Manidipine (Manidipine), nicardipine (Nicardipine), nifedipine (Nifedipine), cilnidipine (Cilnidipine), efonidipine (Efonidipine), barnidipine (Barnidipine), felodipine calcium antagonists such as (Felodipine); Pioglitazone (Pioglitazone), rosiglitazone (Rosiglitazone), Li Gelie ketone (Rivoglitazone), MCC-555, NN-2344, BMS-298585, AZ-242, euglycemic agents such as LY-519818, TAK-559; Pravastatin (Pravastatin), simvastatin (Simvastatin), atorvastatin (Atorvastatin), Rosuvastatin (Rosuvastatin), cerivastatin sodium (Cerivastatin), Pitavastatin (Pitavastatin), fluvastatin HMG-CoA reductase inhibitors such as (Fluvastatin); SMP-797, handkerchief replace wheat cloth ACAT such as (Pactimibe) inhibitor etc., but are not limited to these compositions.Amount to these effective ingredient is not particularly limited, as long as use the used amount of general preparation.
Film-coated preparation of the present invention for example comprises tablet, capsule, powder, granula subtilis, granule, lozenge etc., is preferably tablet.
The manufacture method of film-coated preparation of the present invention, if use Powder Technologyand Pharmaceutical Processes (D.Chulia etc., (December 1 for Elsevier Science PubCo, 1993)) etc. the conventional method manufacturing put down in writing of publication gets final product, and is not particularly limited.
By will containing the film coating liquid of dextrose, need be sprayed by the object of coating and can obtain film-coated preparation with this method preparation to tablet, former medicine etc.Need also can be carried out the bottom coating as required by the object of coating to this.The above-mentioned film matrix of dissolving that in water, suspends and mix above-mentioned additive as required and obtain this film coating liquid.The spraying of film coating liquid can be implemented with the known method such as film coating machine that sell in market.It is created conditions and adopts creating conditions of general film-coated preparation to get final product.
As long as film-coated amount is not particularly limited it for the amount of the abnormal flavour that can effectively reduce medicament and had, but usually with lower limit for prescription weight be that 1% (w/w) is above, more than preferred 3% (w/w), more preferably more than 6% (w/w); The upper limit is that 50% (w/w) is following, preferred 20% (w/w) is following, more preferably the following degree of 10% (w/w) is implemented for prescription weight.
The film thickness of thin layer, so long as the thickness of the abnormal flavour that can effectively reduce medicament and had, just it is not particularly limited, but usually down be limited to that 1 μ m is above, preferred 5 μ m are above, more preferably 10 μ m above, most preferably more than the 20 μ m, on be limited to that 1000Hm is following, preferred 500 μ m are following, more preferably below the 200 μ m, most preferably below the 100 μ m.
Can come the film thickness of MEASUREMENTS OF THIN layer with the colored 3D shape measure microscope VK-9500 of the super degree of depth ((strain) キ one エ Application ス).
The film-coated preparation of the present invention that is obtained carries out administration equally with general preparation and gets final product.
Embodiment
According to embodiment etc., the present invention is elaborated again, but the present invention is not limited thereto below.
(embodiment 1)
After in high-speed stirred comminutor (VG-10, パ ゥ レ ッ Network), mixing 300g olmesartan medoxomil, 1850g lactose, 60g hydroxypropyl emthylcellulose, 175g cross-linking sodium carboxymethyl cellulose; add the 500g distilled water again and carry out pelletize, in fluidized bed drying baker (パ ゥ レ ッ Network), carried out drying.In pelletizing machine (コ one ミ Le, パ ゥ レ ッ Network), the pelletize thing is carried out granulate, coexist with 15g magnesium stearate one and mix in the mixer (V-Mixer, moral longevity make institute).It is 160mg that the gained mixture is made every weight with the R face pestle of the mortar of the diameter 7mm of rotary tablet machine (chrysanthemum water make institute), radius of curvature 8mm, has obtained label.
To the 1000g label that is obtained, use in the 1900g distilled water, dissolved the coating solution of 30g dextrose and 70g sodium carboxymethyl cellulose, with coating machine (De リ ァ コ one one DRC-300, パ ゥ レ ッ Network), to be that the degree of 6% (w/w) is carried out coating for label weight, obtained thin membrane coated tablet (A).
(comparative example 1)
The 1000g label that embodiment 1 is obtained, use is suspended in the coating solution in the 1800g distilled water with 140g hydroxypropyl emthylcellulose, 30g Pulvis Talci, 30g titanium oxide, to be that the degree of 6% (w/w) is carried out coating for label weight, obtained thin membrane coated tablet (B) with coating machine (De リ ァ コ one one DRC-300, パ ゥ レ ッ Network).
(test example 1)
In vial, put into the label of embodiment 1 manufacturing, the thin membrane coated tablet (A) of embodiment 2 manufacturings, the thin membrane coated tablet (B) of comparative example 2 manufacturings and respectively be 30, preserved 3 hours at 40 ℃.Open this vial, following commentary price card standard allows testee 5 people that its abnormal flavour has been carried out sensory test.Its result is as shown in table 1.
The sensory evaluation standard:
＜scoring〉＜content 〉
0: free from extraneous odour
1: abnormal flavour is arranged a little
2: abnormal flavour is arranged
3: very large abnormal flavour is arranged
Table 1: the evaluation of sheet strange smell
| The testee | Label | Thin membrane coated tablet (A) | Thin membrane coated tablet (B) |
| 1 | 3 | 1 | 3 |
| 2 | 3 | 0 | 2 |
| 3 | 3 | 1 | 2 |
| 4 | 3 | 1 | 3 |
| 5 | 3 | 0 | 2 |
| Add up to | 15 | 3 | 12 |
Utilizability on the industry
According to the present invention, can obtain the film-coated preparation that does not in fact have peculiar smell, has the best possible merchandise performance.
Claims (11)
1. film-coated preparation, it contains olmesartan medoxomil in prescription, contain dextrose in the thin layer.
2. film-coated preparation, it contains olmesartan medoxomil and other medicament simultaneously in prescription, contain dextrose in the thin layer.
3. film-coated preparation, it contains 2-amino-5-isobutyl group-4-{2-[5-(N, N '-two ((S)-1-carbethoxyl group) ethyl) phosphonic amide in prescription] furan } thiazole, contain dextrose in the thin layer.
4. as any described film-coated preparation in the claim 1 to 3, in thin layer, also contain coated substrate or excipient.
5. film-coated preparation as claimed in claim 4, its coated substrate or excipient are the chemical compounds more than a kind or 2 kinds that is selected from sodium carboxymethyl cellulose, hydroxymethyl propyl methylcellulose, hydroxypropyl cellulose, polyvinylpyrrolidone, polyvinyl alcohol, methylcellulose, ethyl cellulose, dextrin, maltodextrin, lactose, D-mannitol, polyvinyl alcohol polymer, methacrylic acid copolymer, methacrylic acid ammonia alkyl ester copolymer and the ethyl acrylate methylmethacrylate copolymer.
6. film-coated preparation as claimed in claim 4, coated substrate or excipient are sodium carboxymethyl cellulose.
7. as any described film-coated preparation in the claim 1 to 6, said preparation is a tablet.
8. as any described film-coated preparation in the claim 1 to 7, thin layer is more than 1% (w/w) with respect to prescription weight.
9. as any described film-coated preparation in the claim 1 to 7, thin layer is more than 3% (w/w) with respect to prescription weight.
10. as any described film-coated preparation in the claim 1 to 7, the film thickness of thin layer is more than 1 μ m.
11. as any described film-coated preparation in the claim 1 to 7, the film thickness of thin layer is more than 20 μ m.
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2005147435 | 2005-05-20 | ||
| JP147435/2005 | 2005-05-20 | ||
| PCT/JP2006/309994 WO2006123766A1 (en) | 2005-05-20 | 2006-05-19 | Film coated preparation containing dextrose |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| CN101180052A true CN101180052A (en) | 2008-05-14 |
| CN101180052B CN101180052B (en) | 2010-11-17 |
Family
ID=37431334
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN2006800175368A Active CN101180052B (en) | 2005-05-20 | 2006-05-19 | Film coated preparation containing dextrose |
Country Status (5)
| Country | Link |
|---|---|
| JP (1) | JP4979577B2 (en) |
| KR (1) | KR101314439B1 (en) |
| CN (1) | CN101180052B (en) |
| TW (1) | TWI367756B (en) |
| WO (1) | WO2006123766A1 (en) |
Cited By (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN102716100A (en) * | 2012-07-12 | 2012-10-10 | 南京正大天晴制药有限公司 | Tablets comprising olmesartan medoxomil and method for preparing same |
Families Citing this family (8)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2008050714A1 (en) * | 2006-10-25 | 2008-05-02 | Daiichi Sankyo Company, Limited | Packaging material |
| TWI414310B (en) * | 2006-12-26 | 2013-11-11 | Daiichi Sankyo Co Ltd | Elution-improved pharmaceutical preparation |
| TW200833325A (en) * | 2006-12-26 | 2008-08-16 | Daiichi Sankyo Co Ltd | Pharmaceutical composition comprising ascorbic acid |
| JP2008201711A (en) * | 2007-02-20 | 2008-09-04 | Ss Pharmaceut Co Ltd | Cysteine odor-reduced solid preparation |
| JPWO2009057569A1 (en) * | 2007-10-29 | 2011-03-10 | 第一三共株式会社 | Film coating formulation |
| JP5688799B2 (en) * | 2008-08-11 | 2015-03-25 | 第一三共株式会社 | Odor control method |
| JP4803686B2 (en) * | 2010-08-31 | 2011-10-26 | 協和発酵キリン株式会社 | Granules and orally disintegrating tablets containing a bitter-tasting drug |
| JP6360007B2 (en) * | 2015-06-12 | 2018-07-18 | 富士フイルム株式会社 | Method for producing drug-containing particles |
Family Cites Families (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US6419956B1 (en) * | 1999-12-30 | 2002-07-16 | Ancile Pharmaceuticals | Odor-masking coating for a pharmaceutical preparation |
| JP4107831B2 (en) * | 2000-11-21 | 2008-06-25 | 第一三共株式会社 | Pharmaceutical composition |
| ES2262689T3 (en) * | 2000-11-21 | 2006-12-01 | Sankyo Company, Limited | COMPOSITION CONTAINING AN ANTIGONIST OF THE ANGIOTENSIN II RECEPTOR AND A DIURETIC AND ITS USE FOR THE TREATMENT OF HYPERTENSION. |
| JP4647851B2 (en) * | 2001-08-07 | 2011-03-09 | 日立マクセル株式会社 | The camera module |
| BRPI0406987A (en) * | 2003-01-31 | 2006-01-10 | Sankyo Co | Medicament for the prevention and / or treatment of atherosclerosis, medicaments for inhibiting vascular smooth muscle cell proliferation, neointimal formation of blood vessels and vascular remodeling, medicament for the prevention of restenosis following percutaneous coronary intervention, and, medicines for the prophylaxis and / or treatment of hypertension or diseases caused by hypertension or diseases caused by hypertension, heart disease, angina pectoris, myocardial infarction, arrhythmia, sudden death, heart failure, cardiac hypertrophy, kidney diseases, diabetic nephropathy, glomerulonephritis, nephrosclerosis, cerebrovascular diseases, cerebral infarction, and cerebral hemorrhage |
-
2006
- 2006-05-19 CN CN2006800175368A patent/CN101180052B/en active Active
- 2006-05-19 WO PCT/JP2006/309994 patent/WO2006123766A1/en active Application Filing
- 2006-05-19 JP JP2007516345A patent/JP4979577B2/en active Active
- 2006-05-19 KR KR1020077026730A patent/KR101314439B1/en active IP Right Grant
- 2006-05-19 TW TW095117777A patent/TWI367756B/en active
Cited By (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN102716100A (en) * | 2012-07-12 | 2012-10-10 | 南京正大天晴制药有限公司 | Tablets comprising olmesartan medoxomil and method for preparing same |
Also Published As
| Publication number | Publication date |
|---|---|
| WO2006123766A1 (en) | 2006-11-23 |
| JPWO2006123766A1 (en) | 2008-12-25 |
| KR20080008362A (en) | 2008-01-23 |
| TWI367756B (en) | 2012-07-11 |
| CN101180052B (en) | 2010-11-17 |
| TW200719888A (en) | 2007-06-01 |
| JP4979577B2 (en) | 2012-07-18 |
| KR101314439B1 (en) | 2013-10-07 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CN101171006B (en) | Film coated preparation | |
| CN101180052B (en) | Film coated preparation containing dextrose | |
| CN101842096A (en) | Film-coated preparation | |
| KR101114808B1 (en) | Process for producing coated preparation | |
| CN104220068B (en) | Pharmaceutical composition comprising olmesartan medoxomil and rosuvastatin or its salt | |
| TW200803860A (en) | Stable pharmaceutical composition comprising a pyrimidine-sulfamide | |
| CN101212986B (en) | Stable emulsion composition | |
| ES2569553T3 (en) | Capsule for the prevention of cardiovascular diseases | |
| JP5854571B2 (en) | Odor control method | |
| MXPA02004389A (en) | Pharmaceutical compositions. | |
| TW200819144A (en) | Composition with increased photo-stability | |
| TWI446923B (en) | Coated solid preparation | |
| RU2491058C2 (en) | Galena composition of aliskiren and hydrochlorothiazide | |
| TWI535463B (en) | Coating agent for pharmaceutical solid preparation, film coating preparation for medicine and coated pharmaceutical solid preparation | |
| CN104602678A (en) | Pharmaceutical composite capsule formulation comprising irbesartan and HMG-COA reductase inhibitor | |
| JPH11147819A (en) | Stabilized medicinal preparation | |
| CN102573835B (en) | The film coating piece that discoloration and abnormal smells from the patient are inhibited | |
| CN100496606C (en) | Composite preparation containing nitrate esters medicine and HMG-CoA reductase inhibitor | |
| US20130259935A1 (en) | Pharmaceutical compositions comprising glimepiride and polyethylene glycol castor oil | |
| BR112020006395A2 (en) | combined formulation and its use, method for preparing a combined formulation | |
| CN102361635B (en) | Coated solid preparation | |
| WO2024084496A1 (en) | Pharmaceutical compositions comprising acalabrutinib maleate | |
| WO2019030610A1 (en) | Directly compressible dual drug releasing pharmaceutical compositions |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| C06 | Publication | ||
| PB01 | Publication | ||
| C10 | Entry into substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| C14 | Grant of patent or utility model | ||
| GR01 | Patent grant |